Effects of amisulpride, risperidone and chlorpromazine on auditory and visual latent inhibition, prepulse inhibition, executive function and eye movements in healthy volunteers.
In view of the evidence that cognitive deficits in schizophrenia are critically important for long-term outcome, it is essential to establish the effects that the various antipsychotic compounds have on cognition, particularly second-generation drugs. This parallel group, placebo-controlled study aimed to compare the effects in healthy volunteers (n = 128) of acute doses of the atypical antipsychotics amisulpride (300 mg) and risperidone (3 mg) to those of chlorpromazine (100 mg) on tests thought relevant to the schizophrenic process: auditory and visual latent inhibition, prepulse inhibition of the acoustic startle response, executive function and eye movements. The drugs tested were not found to affect auditory latent inhibition, prepulse inhibition or executive functioning as measured by the Cambridge Neuropsychological Test Battery and the FAS test of verbal fluency. However, risperidone disrupted and amisulpride showed a trend to disrupt visual latent inhibition. Although amisulpride did not affect eye movements, both risperidone and chlorpromazine decreased peak saccadic velocity and increased antisaccade error rates, which, in the risperidone group, correlated with drug-induced akathisia. It was concluded that single doses of these drugs appear to have little effect on cognition, but may affect eye movement parameters in accordance with the amount of sedation and akathisia they produce. The effect risperidone had on latent inhibition is likely to relate to its serotonergic properties. Furthermore, as the trend for disrupted visual latent inhibition following amisulpride was similar in nature to that which would be expected with amphetamine, it was concluded that its behaviour in this model is consistent with its preferential presynaptic dopamine antagonistic activity in low dose and its efficacy in the negative symptoms of schizophrenia.
Barrett
S L
SL
Department of Therapeutics and Pharmacology, Queens University Belfast, Belfast, UK. s.l.barrett@qub.ac.uk
Bell
R
R
Watson
D
D
King
D J
DJ
D000161:Acoustic Stimulation / Q000009:adverse effects; D000284:Administration, Oral; D000328:Adult; D017109:Akathisia, Drug-Induced / Q000209:etiology; D000077582:Amisulpride; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002746:Chlorpromazine / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D018849:Controlled Clinical Trials as Topic; D003710:Demography; D004311:Double-Blind Method; D005133:Eye Movements / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D010775:Photic Stimulation; D011340:Problem Solving / Q000187:drug effects / Q000502:physiology; D011930:Reaction Time / Q000187:drug effects; D013216:Reflex, Startle / Q000187:drug effects / Q000502:physiology; D018967:Risperidone / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D013028:Space Perception / Q000187:drug effects / Q000502:physiology; D013469:Sulpiride / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D014705:Verbal Behavior / Q000187:drug effects / Q000502:physiology
D013469:Sulpiride; D000077582:Amisulpride; D018967:Risperidone; D002746:Chlorpromazine